scholarly journals Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study

2021 ◽  
Vol Volume 17 ◽  
pp. 2637-2646
Author(s):  
Alina Wilkowska ◽  
Adam Włodarczyk ◽  
Maria Gałuszko-Węgielnik ◽  
Mariusz S Wiglusz ◽  
Wiesław J Cubała
2018 ◽  
Vol 32 (10) ◽  
pp. 1110-1117 ◽  
Author(s):  
Rejish K Thomas ◽  
Glen Baker ◽  
John Lind ◽  
Serdar Dursun

Background: Intravenous ketamine has been established as an efficacious and safe treatment, with transient effect, for treatment-resistant depression. However, the effectiveness of intravenous ketamine in non-research settings and with ultraresistant depression patients remains understudied. Aims: This study aims to measure the response and remission rates in ultraresistant depression patients in a clinical setting by means of a retrospective, open label, database study. Secondarily, the study will attempt to support previous findings of clinical predictors of effectiveness with intravenous ketamine treatment. Methods: Fifty patients with ultraresistant depression were treated between May 2015–December 2016, inclusive, in two community hospitals in Edmonton using six ketamine infusions of 0.5 mg/kg over 40 min over 2–3 weeks. Data were collected retrospectively from inpatient and outpatient charts. Statistical analysis to investigate clinical predictors of effectiveness included logistic regression analysis using a dependent variable of a 50% reduction in rating scale score at any point during treatment. Results: At baseline, the average treatment resistance was severe, with a Maudsley Staging Method score of 12.1 out of 15, 90.0% were resistant to electroconvulsive therapy, and the average Beck Depression Inventory score was 34.2. The response rate was 44% and remission rate was 16%. As a single predictor, moderate or severe anhedonia at baseline predicted a 55% increased likelihood of response. As a combined predictor, this level of anhedonia at baseline with a diagnosis of bipolar depression predicted a 73% increase in likelihood of response. Conclusion: In a clinical setting, intravenous ketamine showed effectiveness in a complex, severely treatment-resistant, depressed population on multiple medication profiles concurrently. This study gave support to anhedonia and bipolar depression as clinical predictors of effectiveness.


2018 ◽  
Vol 28 (7) ◽  
pp. 437-444 ◽  
Author(s):  
Kathryn R. Cullen ◽  
Palistha Amatya ◽  
Mark G. Roback ◽  
Christina Sophia Albott ◽  
Melinda Westlund Schreiner ◽  
...  

2020 ◽  
Vol 45 (5) ◽  
pp. 313-321 ◽  
Author(s):  
Victor M. Tang ◽  
Daniel M. Blumberger ◽  
Julia Dimitrova ◽  
Alanah Throop ◽  
Shawn M. McClintock ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document